OBJECTIVE: We studied the efficacy and safety of electively providing surfactant to preterm infants with mild to moderate respiratory distress syndrome (RDS) not requiring mechanical ventilation. STUDY DESIGN: A 5-center, randomized clinical trial was performed on 132 infants with RDS, birth weight >or=1250 grams, gestational age <or=36 weeks, postnatal age 4 to 24 hours, Fio(2) >or=40% for >or=1 hour, and no immediate need for intubation. Infants were randomly assigned to intubation, surfactant (Survanta, Ross Laboratories, Columbus, Ohio) administration, and expedited extubation (n=65) or expectant management (n=67) with subsequent intubation and surfactant treatment as clinically indicated. The primary outcome was duration of mechanical ventilation. RESULTS: Infants in the surfactant group had a median duration of mechanical ventilation of 2.2 hours compared with 0.0 hours for control infants, since only 29 of 67 control infants required mechanical ventilation (P=.001). Surfactant-treated infants were less likely to require subsequent mechanical ventilation for worsening respiratory disease (26% vs 43%, relative risk=0.60; 95% CI, 0.37, 0.99). There were no differences in secondary outcomes (duration of nasal continuous positive airway pressure, oxygen therapy, hospital stay, or adverse outcomes). CONCLUSIONS:Routine elective intubation for administration of surfactant to preterm infants >or=1250 grams with mild to moderate RDS is not recommended.
RCT Entities:
OBJECTIVE: We studied the efficacy and safety of electively providing surfactant to preterm infants with mild to moderate respiratory distress syndrome (RDS) not requiring mechanical ventilation. STUDY DESIGN: A 5-center, randomized clinical trial was performed on 132 infants with RDS, birth weight >or=1250 grams, gestational age <or=36 weeks, postnatal age 4 to 24 hours, Fio(2) >or=40% for >or=1 hour, and no immediate need for intubation. Infants were randomly assigned to intubation, surfactant (Survanta, Ross Laboratories, Columbus, Ohio) administration, and expedited extubation (n=65) or expectant management (n=67) with subsequent intubation and surfactant treatment as clinically indicated. The primary outcome was duration of mechanical ventilation. RESULTS:Infants in the surfactant group had a median duration of mechanical ventilation of 2.2 hours compared with 0.0 hours for control infants, since only 29 of 67 control infants required mechanical ventilation (P=.001). Surfactant-treated infants were less likely to require subsequent mechanical ventilation for worsening respiratory disease (26% vs 43%, relative risk=0.60; 95% CI, 0.37, 0.99). There were no differences in secondary outcomes (duration of nasal continuous positive airway pressure, oxygen therapy, hospital stay, or adverse outcomes). CONCLUSIONS: Routine elective intubation for administration of surfactant to preterm infants >or=1250 grams with mild to moderate RDS is not recommended.
Authors: Anna Maria Hibbs; Dennis Black; Lisa Palermo; Avital Cnaan; Xianqun Luan; William E Truog; Michele C Walsh; Roberta A Ballard Journal: J Pediatr Date: 2009-12-06 Impact factor: 4.406
Authors: Blake Erickson; Stassi C DiMaggio; Douglas G Mullen; Christopher V Kelly; Pascale R Leroueil; Stephanie A Berry; James R Baker; Bradford G Orr; Mark M Banaszak Holl Journal: Langmuir Date: 2008-09-03 Impact factor: 3.882
Authors: Heather C Kaplan; Scott A Lorch; Jennifer Pinto-Martin; Mary Putt; Jeffrey H Silber Journal: BMC Health Serv Res Date: 2011-01-31 Impact factor: 2.655
Authors: Genevieve Taylor; Wesley Jackson; Christoph P Hornik; Alec Koss; Sreekar Mantena; Kenya Homsley; Blair Gattis; Menefese Kudumu-Clavell; Reese Clark; P Brian Smith; Matthew M Laughon Journal: J Pediatr Date: 2018-12-21 Impact factor: 6.314
Authors: Peter A Dargaville; Camille Omar F Kamlin; Antonio G De Paoli; John B Carlin; Francesca Orsini; Roger F Soll; Peter G Davis Journal: BMC Pediatr Date: 2014-08-27 Impact factor: 2.125